丙型肝炎阿拉斯加队列中按纤维化分期评估终末期肝病、肝细胞癌及肝病相关死亡风险
在阿拉斯加美洲印第安人/阿拉斯加原住民丙型肝炎队列中,以肝活检为起点,按Ishak纤维化分期分析终末期肝病、肝细胞癌和肝病相关死亡的发生情况。407人中无/轻度纤维化39%、中度32%、重度22%、肝硬化9%,平均随访7.3年。5年内终末期肝病发生率随纤维化分期加重而升高(P<0.01),肝细胞癌和肝病相关死亡亦随分期加重而升高(P<0.01)。结论认为短期预防肝细胞癌、肝病相关死亡和终末期肝病,丙型肝炎治疗应针对超过轻度纤维化的个体。
要点
- 5年内终末期肝病发生率:无/轻度纤维化1.7%,中度7.9%,重度16.4%,肝硬化49.0%(P<0.01)。
- 5年内肝细胞癌发生率:无/轻度1.0%,中度1.0%,重度1.1%,肝硬化13.4%(P<0.01)。
- 5年内肝病相关死亡:无/轻度0.0%,中度1.0%,重度4.7%,肝硬化16.3%(P<0.01)。
核心结论
- 为短期预防肝细胞癌、肝病相关死亡和终末期肝病,丙型肝炎治疗应针对超过轻度纤维化的个体。
研究设计与样本
- 在阿拉斯加美洲印第安人/阿拉斯加原住民丙型肝炎队列中,以肝活检为起点进行长期前瞻性研究,共407人。
- 按Ishak评分分为无/轻度纤维化(0,1)、中度(2)、重度(3,4)和肝硬化(5,6)。
- 分析终末期肝病、肝细胞癌和肝病相关死亡的发生时间,并报告3、5、7、10年生存概率。
主要发现
- 407人中无/轻度纤维化39%(n=150),中度32%(n=131),重度22%(n=88),肝硬化9%(n=38),平均随访7.3年。
- 活检后5年内终末期肝病发生率:无/轻度1.7%(95%CI 0.4-6.8),中度7.9%(95%CI 4.0-15.2),重度16.4%(95%CI 9.6-27.2),肝硬化49.0%(95%CI 33.0-67.7),P<0.01。
- 活检后5年肝细胞癌发生率:无/轻度1.0%(95%CI 0.1-7.0),中度1.0%(95%CI 0.1-6.6),重度1.1%(95%CI 0.2-7.7),肝硬化13.4%(95%CI 4.4-36.7),P<0.01。
- 活检后5年肝病相关死亡发生率:无/轻度0.0%(95%CI 0.0-14.8),中度1.0%(95%CI 0.2-7.5),重度4.7%(95%CI 1.5-14.1),肝硬化16.3%(95%CI 7.0-35.1),P<0.01。
临床怎么用
- 作者结论认为,为短期预防肝细胞癌、肝病相关死亡和终末期肝病,丙型肝炎治疗应针对超过轻度纤维化的个体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Long-term prospective studies of the outcomes associated with hepatitis C virus (HCV) infection are rare and critical for assessing the potential impact of HCV treatment. Using liver biopsy as a starting point, we analyzed the development of end-stage liver disease (ESLD), hepatocellular carcinoma (HCC), and liver-related death (LRD) according to fibrosis stage among a cohort of American Indian/Alaska Native persons in Alaska. Persons were classified as having no/mild (Ishak = 0,1), moderate (Ishak = 2), or severe (Ishak = 3,4) fibrosis or cirrhosis (Ishak = 5,6). We examined time until development of ESLD, HCC, and LRD and report survival probabilities at 3, 5, 7, and 10 years. Of 407 persons, 39% (n = 150) had no/mild fibrosis, 32% (n = 131) had moderate fibrosis, 22% (n = 88) had severe fibrosis, and 9% (n = 38) had cirrhosis. The average time of follow-up was 7.3 years. Within 5 years of biopsy, 1.7% (95% confidence interval [CI]: 0.4-6.8) of persons with no/mild fibrosis developed ESLD compared with 7.9% (95% CI, 4.0-15.2), 16.4% (95% CI, 9.6-27.2), and 49.0% (95% CI, 33.0-67.7) with moderate, severe fibrosis, and cirrhosis, respectively (P < 0.01). The 5-year outcome of HCC was 1.0% (95% CI, 0.1-7.0), 1.0% (95% CI, 0.1-6.6), 1.1% (95% CI, 0.2-7.7), and 13.4% (95% CI, 4.4-36.7) among persons with no/mild fibrosis, moderate fibrosis, severe fibrosis, and cirrhosis, respectively (P < 0.01). Five years after biopsy, 0.0% (95% CI, 0.0-14.8) of persons with no/mild fibrosis had suffered an LRD compared with 1.0% (95% CI, 0.2-7.5) of persons with moderate fibrosis, 4.7% (95% CI, 1.5-14.1) with severe fibrosis, and 16.3% (95% CI, 7.0-35.1) with cirrhosis (P < 0.01). CONCLUSION: For prevention of HCC, LRD, and ESLD in the short term, HCV therapy should target individuals who have more than mild fibrosis. (Hepatology 2017;66:37-45).
引用
- Bruden DJT, McMahon BJ, Townshend-Bulson L, et al. Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort. Hepatology. 2017. PMID: 28195349. doi:10.1002/hep.29115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。